NASDAQ: SXTP60 Degrees Pharmaceuticals Inc Stock
$1.64+0.02 (+1.23%)
Updated Jun 18, 2026
SXTP Price
$1.64
Fair Value Price
N/A
Market Cap
$4.36M
52 Week Low
$1.23
52 Week High
$10.77
P/E
-0.18x
P/B
0.9x
P/S
7.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$397.44k
Earnings
-$7.58M
Gross Margin
-22.6%
Operating Margin
-1,904.8%
Profit Margin
-2,028.7%
Debt to Equity
0.42
Operating Cash Flow
-$8M
Beta
0.2
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SXTP Overview
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SXTP's potential to beat the market
- SXTP doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SXTP
RankedUnranked of 465
RankedUnranked of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important SXTP news, forecast changes, insider trades & much more!
SXTP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SXTP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SXTP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SXTP is good value based on its book value relative to its share price (0.9x), compared to the US Biotechnology industry average (4.95x)
P/B vs Industry Valuation
SXTP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SXTP due diligence checks available for Premium users.
Valuation
SXTP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.18x
Industry
15.77x
Market
9.47x
SXTP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.9x
Industry
4.95x
SXTP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SXTP's financial health
Profit margin
Revenue
$76.4k
Net Income
-$2.1M
Profit Margin
-2,891.7%
SXTP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SXTP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.8M
Liabilities
$2.0M
Debt to equity
0.42
SXTP's short-term assets ($6.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SXTP's short-term assets ($6.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SXTP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
$1.2M
Financing
$3.4M
SXTP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SXTP vs Biotech Stocks
60 Degrees Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.